| Ticker: | BWAY |
| Current Price: | $10.11 |
| % Daily Change: | -1.37% |
| Volume (1,000s): | 183.58 |
| Average Volume (1,000s): | 125.41 |
| Market Cap (M): | $396.54 |
| 1/2/2024 Price: | $7.22 |
| Change Since Inception: | 40.03% |
BrainsWay Ltd.
Bynet Building
3rd Floor 19 Hartum Street Har Hotzvim
Jerusalem, 9777518
Israel
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives.
BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction.
The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS.